Aurobindo Pharma joins hands with Covaxx for coronavirus vaccine

Aurobindo Pharma Managing Director, N Govindarajan, said: “We are proud to partner with Covaxx in developing the first-ever synthetic peptide-based vaccine to combat the Covid-19 pandemic.”
Aurobindo Pharma and Covaxx, a US-based company, have entered into an exclusive licence agreement to develop, commercialise and manufacture UB-612, the first Multitope Peptide-based vaccine to fight Covid-19, for India and UNICEF.

According to a release issued by the city-based drug maker, Covaxx is currently conducting a Phase 1 clinical trial for the vaccine candidate. Aurobindo Pharma Managing Director, N Govindarajan, said: “We are proud to partner with Covaxx in developing the first-ever synthetic peptide-based vaccine to combat the Covid-19 pandemic.”


Under the signed agreement, Aurobindo Pharma has obtained the exclusive rights to develop, manufacture and sell the vaccine in India and to UNICEF, as well as non-exclusive rights in other select emerging and developing markets, it said.



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel